Tirzepatide
Useful mainly for adults with type 2 diabetes and/or obesity (Zepbound also for moderate-to-severe OSA with obesity) under a prescriber.
Prescription medication — not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with type 2 diabetes and/or obesity (Zepbound also for moderate-to-severe OSA with obesity) under a prescriber
Common dosing range
Titrated to a maintenance dose of 5, 10, or 15 mg subcutaneously once weekly
When to expect effects
Glucose lowering within weeks; substantial weight loss over months (peak around 72 weeks)
Watch out for
Boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma); risk of pancreatitis
What is it
Tirzepatide is a once-weekly dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, given by subcutaneous injection. Acting on both incretin pathways, it improves insulin secretion, suppresses glucagon, slows gastric emptying, and strongly reduces appetite. It is FDA-approved for type 2 diabetes (Mounjaro) and for chronic weight management, including in adults with obstructive sleep apnea and obesity (Zepbound).
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
type 2 diabetes glycemic control Strong Evidence | HbA1c reduction of roughly 1.8-2.4% versus placebo, superior to comparator GLP-1 and insulins | Adults with type 2 diabetes inadequately controlled on diet or other agents | Weeks |
chronic weight management in obesity Strong Evidence | Up to ~21% mean body-weight reduction at the 15 mg dose versus ~3% with placebo at 72 weeks (SURMOUNT-1) | Adults with obesity or overweight with a weight-related condition, without diabetes | Months (continues to ~72 weeks) |
obstructive sleep apnea with obesity Good Evidence | Clinically meaningful reduction in apnea-hypopnea index (AHI) versus placebo at 52 weeks (SURMOUNT-OSA) | Adults with obesity and moderate-to-severe obstructive sleep apnea | Months |
type 2 diabetes glycemic control
- Effect
- HbA1c reduction of roughly 1.8-2.4% versus placebo, superior to comparator GLP-1 and insulins
- Best fit
- Adults with type 2 diabetes inadequately controlled on diet or other agents
- Time
- Weeks
chronic weight management in obesity
- Effect
- Up to ~21% mean body-weight reduction at the 15 mg dose versus ~3% with placebo at 72 weeks (SURMOUNT-1)
- Best fit
- Adults with obesity or overweight with a weight-related condition, without diabetes
- Time
- Months (continues to ~72 weeks)
obstructive sleep apnea with obesity
- Effect
- Clinically meaningful reduction in apnea-hypopnea index (AHI) versus placebo at 52 weeks (SURMOUNT-OSA)
- Best fit
- Adults with obesity and moderate-to-severe obstructive sleep apnea
- Time
- Months
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
type 2 diabetes glycemic control
Biomarker supportThe phase-3 SURPASS program randomized adults with type 2 diabetes and showed tirzepatide lowered HbA1c by approximately 1.8-2.4% with substantial weight loss, outperforming semaglutide 1 mg and basal insulins (degludec, glargine) on glycemic and weight endpoints. A large share of participants reached HbA1c below 5.7% (the non-diabetic range). These trials supported approval for type 2 diabetes as Mounjaro.
Bottom line: Tirzepatide delivers among the largest HbA1c reductions of any incretin therapy in type 2 diabetes.
chronic weight management in obesity
Disease adjunctIn the phase-3 SURMOUNT-1 trial, adults without diabetes who received tirzepatide lost about 15%, 19%, and 21% of body weight at the 5, 10, and 15 mg doses versus roughly 3% with placebo over 72 weeks, with many achieving 20% or more loss. SURMOUNT-2 confirmed substantial (somewhat smaller) loss in type 2 diabetes. Weight is largely regained after discontinuation, consistent with chronic-disease management.
Bottom line: Tirzepatide produces the largest mean weight loss yet seen with an injectable incretin drug, sustained while treatment continues.
obstructive sleep apnea with obesity
Disease adjunctThe SURMOUNT-OSA phase-3 trials randomized adults with obesity and moderate-to-severe obstructive sleep apnea (with and without CPAP) and showed tirzepatide markedly reduced the apnea-hypopnea index versus placebo over 52 weeks, alongside weight loss and improvements in related cardiometabolic measures. This supported the obstructive-sleep-apnea-with-obesity indication for Zepbound. It complements, and does not necessarily replace, airway-directed therapy as judged by the clinician.
Bottom line: In obesity with obstructive sleep apnea, tirzepatide meaningfully lowers the AHI, an FDA-approved use.
How to take it
What to track
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Boxed warning: thyroid C-cell tumors, including medullary thyroid carcinoma, in rodents (human relevance unknown)
Acute pancreatitis
Gallbladder disease (cholelithiasis, cholecystitis)
Acute kidney injury from dehydration with severe GI symptoms
Severe hypoglycemia when combined with insulin or sulfonylureas
Diabetic retinopathy complications in susceptible patients
Possible reduced efficacy of oral hormonal contraceptives around dose initiation/escalation
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma
- People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with prior serious hypersensitivity to tirzepatide
- People with a history of pancreatitis (use with caution)
- Pregnant individuals
Pregnancy & breastfeeding
Not recommended in pregnancy; discontinue when pregnancy is recognized, as weight loss provides no benefit and safety is not established.
Interactions
Additive glucose lowering raises hypoglycemia risk; doses of these often need reduction
Tirzepatide can reduce contraceptive absorption around initiation and dose escalation; a backup or non-oral method is advised for 4 weeks after starting and after each dose increase
Delayed gastric emptying can alter the rate/extent of absorption of co-administered oral drugs
Changed gastric emptying may affect absorption; monitor INR or drug levels
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
References by claim
type 2 diabetes glycemic control
chronic weight management in obesity
Track Tirzepatide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.